Switch theme
Sign up to access all valuation multiples
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
2004
4.5K+
LTM Revenue $1.3B
LTM EBITDA $185M
$10.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Penumbra has a last 12-month revenue (LTM) of $1.3B and a last 12-month EBITDA of $185M.
In the most recent fiscal year, Penumbra achieved revenue of $1.2B and an EBITDA of $46.0M.
Penumbra expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Penumbra valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Profit | $837M | XXX | $755M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $185M | XXX | $46.0M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 4% | XXX | XXX | XXX |
| EBIT | $140M | XXX | $86.2M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $126M | XXX | $14.0M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Penumbra's stock price is $267.
Penumbra has current market cap of $10.3B, and EV of $10.2B.
See Penumbra trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.2B | $10.3B | XXX | XXX | XXX | XXX | $2.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Penumbra has market cap of $10.3B and EV of $10.2B.
Penumbra's trades at 8.5x EV/Revenue multiple, and 221.4x EV/EBITDA.
Equity research analysts estimate Penumbra's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Penumbra has a P/E ratio of 81.8x.
See valuation multiples for Penumbra and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.3B | XXX | $10.3B | XXX | XXX | XXX |
| EV (current) | $10.2B | XXX | $10.2B | XXX | XXX | XXX |
| EV/Revenue | 8.1x | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBITDA | 55.1x | XXX | 221.4x | XXX | XXX | XXX |
| EV/EBIT | 72.7x | XXX | 118.1x | XXX | XXX | XXX |
| EV/Gross Profit | 12.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 81.8x | XXX | 737.8x | XXX | XXX | XXX |
| EV/FCF | 54.6x | XXX | 69.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPenumbra's last 12 month revenue growth is 13%
Penumbra's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Penumbra's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Penumbra's rule of X is 48% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Penumbra and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 40% | XXX | 46% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Penumbra acquired XXX companies to date.
Last acquisition by Penumbra was XXXXXXXX, XXXXX XXXXX XXXXXX . Penumbra acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Penumbra founded? | Penumbra was founded in 2004. |
| Where is Penumbra headquartered? | Penumbra is headquartered in United States of America. |
| How many employees does Penumbra have? | As of today, Penumbra has 4.5K+ employees. |
| Who is the CEO of Penumbra? | Penumbra's CEO is Mr. Adam Elsesser. |
| Is Penumbra publicy listed? | Yes, Penumbra is a public company listed on NYS. |
| What is the stock symbol of Penumbra? | Penumbra trades under PEN ticker. |
| When did Penumbra go public? | Penumbra went public in 2015. |
| Who are competitors of Penumbra? | Similar companies to Penumbra include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Penumbra? | Penumbra's current market cap is $10.3B |
| What is the current revenue of Penumbra? | Penumbra's last 12 months revenue is $1.3B. |
| What is the current revenue growth of Penumbra? | Penumbra revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Penumbra? | Current revenue multiple of Penumbra is 8.1x. |
| Is Penumbra profitable? | Yes, Penumbra is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Penumbra? | Penumbra's last 12 months EBITDA is $185M. |
| What is Penumbra's EBITDA margin? | Penumbra's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Penumbra? | Current EBITDA multiple of Penumbra is 55.1x. |
| What is the current FCF of Penumbra? | Penumbra's last 12 months FCF is $187M. |
| What is Penumbra's FCF margin? | Penumbra's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Penumbra? | Current FCF multiple of Penumbra is 54.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
